Pds biotech reports third quarter 2023 financial results and provides business update

Princeton, n.j., nov. 14, 2023 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb) (“pds biotech” or the “company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the company's proprietary t cell activating platforms, today announced its financial results for the quarter ended september 30, 2023. the company will provide a business update on its conference call and webcast at 8:00 am est today.
PDSB Ratings Summary
PDSB Quant Ranking